Home >> HLCL-61
Related Products
HLCL-61 PRMT5 inhibitor

Catalog No.B7806
Size Price Stock Qty
5mg
$68.00
In stock
25mg
$208.00
In stock
100mg
$488.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

HLCL-61

HLCL-61 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

HLCL-61 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 1158279-20-9 SDF Download SDF
Chemical Name 1-(9-ethyl-9H-carbazol-3-yl)-N-(2-methoxybenzyl)methanamine hydrochloride
Canonical SMILES CCN1C2=CC=CC=C2C3=C1C=CC(CNCC4=CC=CC=C4OC)=C3.Cl
Formula C23H25ClN2O M.Wt 380.91
Solubility Soluble in DMSO Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

Background

HLCL-61 is a PRMT5 inhibitor.

Aberrant methylation of protein arginine residues mediated by protein arginine methyltransferase (PRMT) enzymes is reported to be linked to cancer. PRMTs are a family of proteins with 11 known members catalyzing the transfer of methyl group(s) to the guanidine nitrogen atoms of peptide arginine residues. PRMT5 has multiple substrates including histones and other non-chromatin proteins and has been gained attention for cancer therapy.

In vitro: In previous study, HLCL-61 showed no inhibitory activity against PRMT1, PRMT4, and type II PRMT family members, therefore demonstrating its specificity for PRMT5. HLCL-61 also showed effective inhibition of symmetric arginine dimethylation of histones H3 and H4, starting at 12 h posttreatment and persisting for 48 h. Moreover, the treatment of AML cell lines and primary blasts with HLCL-61 led to the decrease of cell viability. In addition, HLCL-61-treated AML cell lines and patient samples had induction of differentiation as demonstrated by dose-dependent increases in the expression of CD11b. Furthermore, PRMT5 inhibition caused by HLCL-61 treatment led to a decrease in MV4-11 cells [1].

In vivo: So far, there is no animal in vivo data reported.

Clinical trial: Up to now, HLCL-61 is still in the preclinical development stage.

Reference:
[1] Tarighat SS et al.  The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation. Leukemia. 2016 Apr;30(4):789-99.